Clinical Trials Logo

Metastatic Prostate Cancer clinical trials

View clinical trials related to Metastatic Prostate Cancer.

Filter by:

NCT ID: NCT00599313 Completed - Clinical trials for Metastatic Prostate Cancer

Phase II Sunitinib Prog Met AIPC

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.

NCT ID: NCT00541281 Completed - Clinical trials for Metastatic Prostate Cancer

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Start date: December 2003
Phase: Phase 2
Study type: Interventional

we propose to randomize patients with hormone resistant prostate cancer between docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The principal endpoint will be the efficacy in term of PSA response.

NCT ID: NCT00494338 Terminated - Clinical trials for Metastatic Prostate Cancer

Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

Start date: November 2004
Phase: Phase 2
Study type: Interventional

A multi-center controlled, non-comparative open Phase II trial of docetaxel and celecoxib in patients with metastatic androgen independent prostate cancer where efficacy is measured by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart.

NCT ID: NCT00452387 Terminated - Clinical trials for Metastatic Prostate Cancer

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Start date: May 2007
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if the combination of mitoxantrone, prednisone and sorafenib will improve the time to progression of advanced stage metastatic hormone-refractory prostate cancer.

NCT ID: NCT00441571 Recruiting - Clinical trials for Metastatic Prostate Cancer

Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer

CYT-500
Start date: February 2007
Phase: Phase 1
Study type: Interventional

The proposed phase 1 clinical trial will investigate the safety and tolerability of 177Lu-CYT-500 in patients with metastatic prostate cancer and determine the optimal antibody mass and dose of 177Lu to be used for further study.

NCT ID: NCT00439270 Completed - Clinical trials for Metastatic Prostate Cancer

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Start date: July 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.

NCT ID: NCT00415779 Completed - Clinical trials for Metastatic Prostate Cancer

ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer

ZANTE
Start date: July 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of docetaxel when given with zoledronic acid in patients with bone metastasis from prostate cancer that has not responded to hormone therapy.

NCT ID: NCT00255268 Withdrawn - Clinical trials for Metastatic Prostate Cancer

CMAB vs IMAB in Metastatic Prostate Cancer

Start date: August 2004
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

NCT ID: NCT00216060 Terminated - Clinical trials for Metastatic Prostate Cancer

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Start date: October 2003
Phase: Phase 3
Study type: Interventional

Risedronate is an orally administered pyridinyl bisphosphonate that is 36 times more potent than pamidronate and 72 times more potent than clodronate. Four randomized, double-blind trials have been carried out in patients with postmenopausal osteoporosis. In 2 of these studies, vertebral fracture incidence was reduced by a daily dose of 5 mg risedronate by up to 65% and 49% relative to placebo after 1 and 3 years, respectively. In these trials, risedronate improved lumbar spine, femoral neck, and femoral trochanter bone mineral density (BMD) at 6 months. In addition, preclinical studies have shown that risedronate is more potent than pamidronate and clodronate in inhibiting adhesion of prostate cancer cells to bone and preventing tumor cell invasion. The incidence of osteoporosis in prostate cancer patients has been well established; therefore, it is advantageous to assess the efficacy of oral bisphosphonate therapy.

NCT ID: NCT00213694 Completed - Clinical trials for Metastatic Prostate Cancer

PROSTACOX : Metastatic Prostate Chemotherapy

Start date: November 2003
Phase: Phase 2
Study type: Observational

Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.